Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).Mamta Parikh, Nataliya Mar, Amanda Macaraeg et al.|Journal of Clinical Oncology|2026Cited by 0